 Brownlee also gave Purdue Pharma immunity from further prosecution up to and for future offenses after this plea deal, continuing until 2007.As the company continued selling Oxycontin without restriction after their conviction, The New York Times claimed that "Purdue suffered a crushing defeat in May at the hands of Brownlee when the company and three top executives pleaded guilty to criminal charges.